Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Necitumumab + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Necitumumab||Portrazza||IMC-11F8||EGFR Antibody 51||Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 26||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02789345||Phase I||Osimertinib + Ramucirumab Necitumumab + Osimertinib||A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer||Completed||USA | FRA | ESP||2|
|NCT03944772||Phase II||Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib||Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)||Recruiting||USA | ITA | ESP | CAN||6|
|NCT02496663||Phase I||Necitumumab + Osimertinib||Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor||Active, not recruiting||USA||0|